Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05659719 · ClinicalTrials.gov registry record
A Study to Learn About Recifercept in Patients With Achondroplasia
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 248
- Enrollment target
NCT05659719 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 248 participants.
The verdict
NCT05659719 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 248 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the study medicine (called recifercept) in people with achondroplasia. Achondroplasia is a very rare disease and patients of achondroplasia have short arms and legs. The study will include data already collected from a recifercept clinical trial and data collected from a separate study of achondroplasia. This study will compare patient experiences and will help the investigators determine if the study medicine, recifercept, is effective.
Interventions
- OTHER Recifercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2022-10-19 |
| Est. Completion | 2023-05-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05659719
The ClinicalTrials.gov registry entry for NCT05659719 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recifercept is the first listed.
NCT05659719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05659719 about?
NCT05659719 is a clinical study titled "A Study to Learn About Recifercept in Patients With Achondroplasia". The purpose of this study is to learn about the study medicine (called recifercept) in people with achondroplasia. Achondroplasia is a very rare disease and patients of achondroplasia have short arms and legs. The study will include data already collected from a recifercept clinical trial and data c...
What is the current status of trial NCT05659719?
This trial is currently completed. The enrollment target is 248 participants. The study started on 2022-10-19. Estimated completion is 2023-05-16.
What interventions are being tested in trial NCT05659719?
The interventions under investigation include: Recifercept (OTHER).
Who is sponsoring clinical trial NCT05659719?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.